Nasdaq Rises by 150 Points; Planet Labs Stock Soars Following Q2 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 08 2025
0mins
Source: Benzinga
Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite gaining approximately 150 points, while the Dow decreased by 0.20%. The S&P 500 also saw a slight increase of 0.20%.
Sector Movements: Information technology stocks rose by 1.1%, whereas real estate stocks fell by 1%. Notable stock movements included Planet Labs PBC surging 14% after better-than-expected earnings, while New Fortress Energy Inc. dropped 40% due to disappointing financial results.
Analyst Views on RAPP
Wall Street analysts forecast RAPP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPP is 54.60 USD with a low forecast of 40.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.450
Low
40.00
Averages
54.60
High
80.00
Current: 26.450
Low
40.00
Averages
54.60
High
80.00
About RAPP
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for refractory focal epilepsy, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
